Lee to take the helm at SK Biopharmaceuticals
Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
EVP Donghoon Lee will become president and CEO of SK Biopharmaceuticals Co. Ltd. (KSE:326030) and its U.S. subsidiary, SK Life Science, effective Jan. 1, 2023. Lee, who is also head of SK’s Bio Investment Center, succeeds CEO Jeong Cho, who will transition over to the role of president of future growth. A second investment center employee, VP Jonggil Choi, is also transitioning over to SK Biopharmaceuticals — he will become VP of global strategy. SK said the changes were to strengthen SK Biopharmaceuticals as SK Group’s key bio business.
Drug discovery and development company insitro Inc. hired Philip Tagari as CSO, effective early 2023. Tagari is a 24-year veteran of Amgen Inc. (NASDAQ:AMGN), where he is VP of research in therapeutic discovery, a role he has held for over a decade. ...